Nucleus Network (formerly Q-Pharm)

Nucleus Network, formerly known as Q-Pharm, is dedicated to advancing medicine and improving lives. The Brisbane facility, located at the Royal Brisbane and Women’s Hospital, is Australia's second largest Phase 1 unit, with a strong focus on conducting clinical trials for companies and researchers developing new, safer, or more effective medicines.

Key benefits of conducting clinical trials at Nucleus Network (formerly Q-Pharm) include: reliable and extensive experience over 15 years with 400+ Early Phase studies successfully completed and 15000+ participants recruited; fast clinical trial start-up of approximately 4-6 weeks from ethics submission to commencement; frequent dates for ethics submission with 40 meetings per year; completion of clinical trials on time and within budget; an excellent working relationship with local and commercial HREC; inspection by regulatory bodies such as FDA, AFSSAPS, AEMPS, and ANVISA; and data acceptance worldwide by regulators.

Founded in 2004, Nucleus Network provides a safe location for conducting trials with a high level of IP protection and a low-risk, stable destination. Despite the absence of specific investment and industry information, the track record and capabilities of Nucleus Network make it an attractive opportunity for potential investors looking to support advancements in clinical research and the development of new medications.